ClinicalTrials.gg
CompletedNCT02782468Updated Nov 3, 2023Results posted

A Study of Pevonedistat in Adult East Asian Participants

A Phase 1 interventional study of Pevonedistat 25 mg/m^2 and Pevonedistat 44 mg/m^2 in Leukemia, Myeloid, Acute and Myelodysplastic Syndromes, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-03.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing pevonedistat in Leukemia, Myeloid, Acute — 1 open to participants now, 4 under way, 2 of them phase 3. pevonedistat · Leukemia, Myeloid, Acute.

Enrollment
9th of 17
23 · median 23
Started
2016
with 2 others
Phase 1
9 of 17
none open now
Registered
4th of 17
by date
Lead sponsor
4 of 17
Millennium Pharmaceuticals, Inc.

Among the 17 studies testing pevonedistat in Leukemia, Myeloid, Acute, this one is the 9th largest by enrollment, is one of 3 that started in 2016, is one of 9 in phase 1, and was the 4th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

1 of the 17 studies testing pevonedistat in Leukemia, Myeloid, Acute is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About pevonedistat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing pevonedistat in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of pevonedistat administered as a single agent and in combination with azacitidine in adult east Asian participants with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).

Read the detailed description

The drug being tested in this study is called Pevonedistat. Pevonedistat is being tested to treat people with myelodysplastic syndromes MDS (including nonproliferative chronic myelomonocytic leukemia [CMML]) and AML (acute myeloid leukaemia) as a single-agent and in combination treatment with azacitidine. This study will look at the safety and tolerability, the recommended phase 2/phase 3 dose of pevonedistat administered in combination with azacitidine, pharmacokinetics and response to treatment in participants who take single agent pevonedistat compared to participants who take pevonedistat and azacitidine.

The study will enroll approximately 37 participants. Participants will be assigned into one of the four treatment groups which will remain disclosed to the patient and study doctor during the study. Participants will be first enrolled at single-agent low dose level (25 mg/m\^2). If this dose is tolerable, participants will be enrolled in parallel at single-agent higher dose level (44 mg/m\^2) and in combination treatment cohorts.

  • Pevonedistat 25 mg/m\^2
  • Pevonedistat 44 mg/m\^2
  • Pevonedistat 10 mg/m\^2 and azacitidine 75 mg/m\^2 combination
  • Pevonedistat 20 mg/m\^2 and azacitidine 75 mg/m\^2 combination Participants will receive pevonedistat infusion intravenously and azacitidine via intravenous or subcutaneous route.

This multi-center trial will be conducted in Japan, Korea and Taiwan. The overall time to participate in this study is approximately 24 months. Participants will attend the End of Study (EOS) visit for safety, 30 days after receiving their last dose of study drug or before the start of subsequent antineoplastic therapy (other than hydroxyurea).

03

Conditions studied

  • Leukemia, Myeloid, Acute
  • Myelodysplastic Syndromes

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. East Asian patients aged 18 years or older (or minimum age of legal consent consistent with local regulations) when written study is obtained must meet 1 of the following diagnosis criteria for either the Single-Agent Arm or the Combination Arm (additional restrictions apply to the Single Agent Arm):

    a. Are male and female participants with WHO-defined AML, including leukemia secondary to prior chemotherapy or resulting from an antecedent hematologic disorder, who have failed to achieve CR or who have after prior therapy (R/R) and are not candidates for potentially curative treatment, or ii. Are male and female participants aged 60 years or older with previously untreated AML who have bone marrow blasts \<30% and who are not candidates for standard induction chemotherapy, or iii. Are male and female participants with WHO-defined MDS that meets the IPSS-R criteria for the very high, high, or intermediate risk group, for whom standard curative, life-prolonging treatment does not exist or is no longer effective (R/R), or iv. Are male and female participants with previously untreated MDS that meets the IPSS-R criteria for the very high, high, or intermediate risk group, or vi. Are male and female participants with WHO-defined CMML-2 or CMML-1 that meets the IPSS-R criteria for the very high, high, or intermediate risk group CMML-1 participants must have bone marrow blasts >=5%

  2. Has (ECOG) performance status of 0 to 1.
  3. Able to undergo bone marrow aspiration and at Screening.

Exclusion criteria

Exclusion Criteria include, in part:

  1. Acute promyelocytic leukemia (as diagnosed by morphologic examination of bone marrow, by fluorescent in situ hybridization or cytogenetics [t (15:17)] of peripheral blood or bone marrow, or by other accepted analysis) or AML associated with t (9;22) karyotypes or molecular.
  2. More than 3 (Combination Arm only).
  3. Prior therapy with hypomethylating agents (example, azacitidine, decitabine). (Combination Arm only).
  4. Is eligible for a hematopoietic stem cell transplant.
  5. Is a female participant who is lactating and breastfeeding or who have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.
  6. Had treatment with any products within 14 days before the first dose of any study drug.
  7. Has known to azacitidine or mannitol (Combination Arm only).
  8. Has known central nervous system involvement.
  9. Had systemic antineoplastic therapy or radiotherapy within 14 days before the first dose of any study drug, except for hydroxyurea.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Arm 1, Cohort 1: Pevonedistat 25 mg/m^2

    Pevonedistat, 25 milligram per square meter (mg/m\^2), 60-minute infusion, intravenously, on Days 1, 3 and 5, followed by a rest period of 16 days, in 21-day treatment cycles.

    Drug: Pevonedistat 25 mg/m^2

  • Experimental
    Arm 1, Cohort 2: Pevonedistat 44 mg/m^2

    Pevonedistat, 44 mg/m\^2, 60-minute infusion, intravenously, on Days 1, 3, and 5, followed by a rest period of 16 days, in 21-day treatment cycles.

    Drug: Pevonedistat 44 mg/m^2

  • Experimental
    Arm 2, Cohort 1: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2

    Pevonedistat 10 mg/m\^2, 60-minute infusion, intravenously, on Days 1, 3, and 5 and azacitidine 75 mg/m\^2, on Days 1 to 5, and Days 8 and 9, intravenously or subcutaneously, followed by a rest period of 19 days, in 28-day treatment cycles.

    Drug: Pevonedistat 10 mg/m^2 · Drug: Azacitidine 75 mg/m^2

  • Experimental
    Arm 2, Cohort 2: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2

    Pevonedistat 20 mg/m\^2, 60-minute infusion, intravenously, on Days 1, 3, and 5 and azacitidine 75 mg/m\^2, on Days 1 to 5, and Days 8 and 9, intravenously or subcutaneously, followed by a rest period of 19 days, in 28-day treatment cycles.

    Drug: Pevonedistat 20 mg/m^2 · Drug: Azacitidine 75 mg/m^2

Interventions

  • DrugPevonedistat 25 mg/m^2

    Drug page: Pevonedistat

    Pevonedistat 25 mg/m\^2 intravenous infusion.

  • DrugPevonedistat 44 mg/m^2

    Drug page: Pevonedistat

    Pevonedistat 44 mg/m\^2 intravenous infusion.

  • DrugPevonedistat 10 mg/m^2

    Drug page: Pevonedistat

    Pevonedistat 10 mg/m\^2 intravenous infusion.

  • DrugPevonedistat 20 mg/m^2

    Drug page: Pevonedistat

    Pevonedistat 20 mg/m\^2 intravenous infusion.

  • DrugAzacitidine 75 mg/m^2

    Drug page: Azacitidine

    Azacitidine 75 mg/m\^2 intravenous or subcutaneous formulation.

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From first dose through 30 days after the last dose of study drug: single agent arms (up to Cycle 19 [up to Day 429]) (Cycle=21 days); combination arms (up to Cycle 65 [up to Day 1850]) (Cycle=28 days)

  2. Number of Participants With Dose Limiting Toxicities (DLTs) Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 During Cycle 1

    DLT: Any of following events considered possibly related to study drug(s) by investigator: Grade (G) 3 or greater nausea and/or emesis despite use of optimal antiemetic prophylaxis; G3 diarrhea occurred despite maximal supportive therapy; G3 arthralgia/myalgia despite use of optimal analgesia; G3 nonhematologic toxicity with exceptions: 1) Brief fatigue, 2) hypophosphatemia; Persistent elevations of transaminases/bilirubin above G2 beyond 2 days between doses; Other study drug-related nonhematologic toxicities G2 or greater, required a dose reduction/discontinuation of pevonedistat. G3 or greater hematologic toxicities, including G3 or 4 febrile neutropenia, considered DLTs if: A delay in initiation of Cycle 2 due to lack of adequate recovery from treatment-related toxicity: 1) Of more than (\>) 4 weeks due to hematologic toxicity believed not related to leukemic infiltration. Bone marrow (BM) evaluation may have been required. 2) Of \>2 weeks due to nonhematologic toxicities.

    Time frame: Cycle 1 (Cycle length = 21 days [single agent arms]; 28 days [combination arms])

  3. Number of Participants With Clinically Significant Abnormal Laboratory Values

    Time frame: Baseline up to Cycle 19 (up to Day 399) in single agent arms (Cycle=21days) and Cycle 65 (up to Day 1820) in combination arms (Cycle=28 days)

  4. Cmax: Maximum Observed Plasma Concentration for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 1

    Time frame: Cycle 1 Day 1: pre-infusion and at multiple time points (up to 48 hours) post-infusion (Cycle length = 21 days [single agent arms]; 28 days [combination arms])

  5. Cmax: Maximum Observed Plasma Concentration for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5

    Time frame: Cycle 1 Day 5: pre-infusion and at multiple time points (up to 48 hours) post-infusion (Cycle length = 21 days [single agent arms]; 28 days [combination arms])

  6. AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5

    Time frame: Cycle 1 Day 5: pre-infusion and at multiple time points (up to 48 hours) post-infusion (Cycle length = 21 days [single agent arms]; 28 days [combination arms])

  7. CL: Total Clearance for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 1

    Time frame: Cycle 1 Day 1: pre-infusion and at multiple time points (up to 48 hours) post-infusion (Cycle length = 21 days [single agent arms]; 28 days [combination arms])

  8. CL: Total Clearance for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5

    Time frame: Cycle 1 Day 5: pre-infusion and at multiple time points (up to 48 hours) post-infusion (Cycle length = 21 days [single agent arms]; 28 days [combination arms])

Secondary outcomes

  1. Overall Response Rate (ORR) for Participants With AML

    ORR for AML was defined as the percentage of participants with a complete remission (CR), CR with incomplete blood count recovery (CRi), or partial remission (PR) based on Modified International Working Group (IWG) Response Criteria for AML. CR was defined as participant achieved the morphologic leukemia-free state and had an absolute neutrophil count (ANC) of more than 1,000 per microliter (/mcL) and platelets of greater than or equal to (\>=) 100,000/mcL. A morphologic leukemia-free state requires less than (\<) 5 percent (%) blasts in an aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. CRi was, after chemotherapy, some participants who fulfilled all of the criteria for CR except for residual neutropenia (\<1,000/mcL) or thrombocytopenia (\<100,000/mcL). PR designation required all the hematologic values for a CR but with a decrease of at least 50% in the percentage of blasts to between 5% and 25% in the bone marrow aspirate.

    Time frame: From first dose up to 30 days after last dose of study drug or before start of subsequent antineoplastic therapy, whichever comes earlier up to Cycle 19 (up to Day 429, single agent)(Cycle=21 days) and Cycle 65 (up to Day 1850, combination)(Cycle=28 days)

  2. ORR for Participants With MDS

    ORR for MDS: Percentage of participants with CR,PR or hematologic improvement(HI) based on IWG Response Criteria. CR: BM:\<=5% myeloblasts with normal maturation of all cell lines; persistent dysplasia noted peripheral blood: hemoglobin (Hgb)\>=11 gram per deciliter (g/dL),platelets\>=100\*10\^9/L,neutrophils \>=1.0\*10\^9/L, blasts 0%. PR:CR criteria if abnormal before treatment except: BM blasts decreased by \>=50% from pretreatment but still\>5%; cellularity, morphology not relevant. HI criteria: Erythroid response:Hgb up by \>=1.5 g/dL; transfused RBC reduced by at least 4 red blood cell (RBC) transfusions/8 weeks comparatively last 8 weeks; Platelet response: Increase of \>=30\*10\^9/L for participants starting with \>20\*10\^9/L platelets; increase from \<20\*10\^9/L to \>20\*10\^9/L and by 100%; Neutrophil response: At least 100% and absolute increase \>0.5\*10\^9/L; Progression/relapse after HI: Granulocytes/platelets decreased by 50% from maximum; Hgb reduced by \>=1.5 g/dL; transfusion dependence.

    Time frame: From first dose up to 30 days after last dose of study drug or before start of subsequent antineoplastic therapy, whichever comes earlier up to Cycle 19 (up to Day 429, single agent)(Cycle=21 days) and Cycle 65 (up to Day 1850, combination)(Cycle=28 days)

  3. Percentage of Participants With CR for Participants With AML

    CR was defined as participant achieved the morphologic leukemia-free state and had an ANC of more than 1,000/mcL and platelets of \>=100,000/mcL. A morphologic leukemia-free state requires \<5% blasts in an aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. CR assessment was based on IWG Response Criteria.

    Time frame: From first dose up to 30 days after last dose of study drug or before start of subsequent antineoplastic therapy, whichever comes earlier up to Cycle 19 (up to Day 429, single agent)(Cycle=21 days) and Cycle 65 (up to Day 1850, combination)(Cycle=28 days)

  4. Percentage of Participants With CR for Participants With MDS

    CR was defined as participant with bone marrow: less than or equal to (\<=) 5% myeloblasts with normal maturation of all cell lines; persistent dysplasia was noted peripheral blood: Hgb \>=11 g/dL, platelets \>=100\*10\^9/L, neutrophils \>=1.0\*10\^9 per liter (/L), blasts 0%. CR assessment was based on IWG Response Criteria.

    Time frame: From first dose up to 30 days after last dose of study drug or before start of subsequent antineoplastic therapy, whichever comes earlier up to Cycle 19 (up to Day 429, single agent)(Cycle=21 days) and Cycle 65 (up to Day 1850, combination)(Cycle=28 days)

07

Results

Posted Nov 3, 2023

Participant flow

Participants took part in the study at 8 investigative sites in Japan, Taiwan and South Korea from 16 May 2016 to 25 January 2022.

Participant flow — Overall Study
MilestoneSingle Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2
Started37310
Completed0000
Not completed37310
Withdrew: Progressive disease2504
Withdrew: Adverse event0223
Withdrew: Other0011
Withdrew: Initiation of hematopoietic stem cell transplant0001
Withdrew: Symptomatic deterioration0001
Withdrew: Withdrawal by subject1000

Outcome measures

PrimaryNumber of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
From first dose through 30 days after the last dose of study drug: single agent arms (up to Cycle 19 [up to Day 429]) (Cycle=21 days); combination arms (up to Cycle 65 [up to Day 1850]) (Cycle=28 days)
Reported as:
Count of participants · Participants
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsSingle Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2
TEAEs37310
SAEs2736
PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs) Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 During Cycle 1

DLT: Any of following events considered possibly related to study drug(s) by investigator: Grade (G) 3 or greater nausea and/or emesis despite use of optimal antiemetic prophylaxis; G3 diarrhea occurred despite maximal supportive therapy; G3 arthralgia/myalgia despite use of optimal analgesia; G3 nonhematologic toxicity with exceptions: 1) Brief fatigue, 2) hypophosphatemia; Persistent elevations of transaminases/bilirubin above G2 beyond 2 days between doses; Other study drug-related nonhematologic toxicities G2 or greater, required a dose reduction/discontinuation of pevonedistat. G3 or greater hematologic toxicities, including G3 or 4 febrile neutropenia, considered DLTs if: A delay in initiation of Cycle 2 due to lack of adequate recovery from treatment-related toxicity: 1) Of more than (\>) 4 weeks due to hematologic toxicity believed not related to leukemic infiltration. Bone marrow (BM) evaluation may have been required. 2) Of \>2 weeks due to nonhematologic toxicities.

Time frame:
Cycle 1 (Cycle length = 21 days [single agent arms]; 28 days [combination arms])
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs) Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 During Cycle 1
ParticipantsSingle Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2
Number of Participants With Dose Limiting Toxicities (DLTs) Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 During Cycle 10001
PrimaryNumber of Participants With Clinically Significant Abnormal Laboratory Values
Time frame:
Baseline up to Cycle 19 (up to Day 399) in single agent arms (Cycle=21days) and Cycle 65 (up to Day 1820) in combination arms (Cycle=28 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Laboratory Values
ParticipantsSingle Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2
Number of Participants With Clinically Significant Abnormal Laboratory Values0000
PrimaryCmax: Maximum Observed Plasma Concentration for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 1
Time frame:
Cycle 1 Day 1: pre-infusion and at multiple time points (up to 48 hours) post-infusion (Cycle length = 21 days [single agent arms]; 28 days [combination arms])
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 1
nanogram per milliliter (ng/mL)Single Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2
Cmax: Maximum Observed Plasma Concentration for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 1253 ± 37.6410 ± 45.567.0 ± 5.9160 ± 25.7
PrimaryCmax: Maximum Observed Plasma Concentration for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5
Time frame:
Cycle 1 Day 5: pre-infusion and at multiple time points (up to 48 hours) post-infusion (Cycle length = 21 days [single agent arms]; 28 days [combination arms])
Reported as:
Geometric mean · ng/mL
Cmax: Maximum Observed Plasma Concentration for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5
ng/mLSingle Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2
Cmax: Maximum Observed Plasma Concentration for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5252 ± 9.9453 ± 38.776.1 ± 17.6170 ± 33.7
PrimaryAUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5
Time frame:
Cycle 1 Day 5: pre-infusion and at multiple time points (up to 48 hours) post-infusion (Cycle length = 21 days [single agent arms]; 28 days [combination arms])
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5
hour*nanogram per milliliter (h*ng/mL)Single Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2
AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 51515 ± 9.12163 ± 25.7647 ± 41.31224 ± 14.9
PrimaryCL: Total Clearance for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 1
Time frame:
Cycle 1 Day 1: pre-infusion and at multiple time points (up to 48 hours) post-infusion (Cycle length = 21 days [single agent arms]; 28 days [combination arms])
Reported as:
Geometric mean · liter per hour
CL: Total Clearance for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 1
liter per hourSingle Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2
CL: Total Clearance for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 124.1 ± 20.132.6 ± 41.722.8 ± 48.828.4 ± 23.9
PrimaryCL: Total Clearance for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5
Time frame:
Cycle 1 Day 5: pre-infusion and at multiple time points (up to 48 hours) post-infusion (Cycle length = 21 days [single agent arms]; 28 days [combination arms])
Reported as:
Geometric mean · liter per hour
CL: Total Clearance for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5
liter per hourSingle Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2
CL: Total Clearance for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 524.0 ± 23.034.8 ± 34.628.1 ± 38.328.9 ± 23.7
SecondaryOverall Response Rate (ORR) for Participants With AML

ORR for AML was defined as the percentage of participants with a complete remission (CR), CR with incomplete blood count recovery (CRi), or partial remission (PR) based on Modified International Working Group (IWG) Response Criteria for AML. CR was defined as participant achieved the morphologic leukemia-free state and had an absolute neutrophil count (ANC) of more than 1,000 per microliter (/mcL) and platelets of greater than or equal to (\>=) 100,000/mcL. A morphologic leukemia-free state requires less than (\<) 5 percent (%) blasts in an aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. CRi was, after chemotherapy, some participants who fulfilled all of the criteria for CR except for residual neutropenia (\<1,000/mcL) or thrombocytopenia (\<100,000/mcL). PR designation required all the hematologic values for a CR but with a decrease of at least 50% in the percentage of blasts to between 5% and 25% in the bone marrow aspirate.

Time frame:
From first dose up to 30 days after last dose of study drug or before start of subsequent antineoplastic therapy, whichever comes earlier up to Cycle 19 (up to Day 429, single agent)(Cycle=21 days) and Cycle 65 (up to Day 1850, combination)(Cycle=28 days)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) for Participants With AML
percentage of participantsSingle Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2
Overall Response Rate (ORR) for Participants With AML005080
SecondaryORR for Participants With MDS

ORR for MDS: Percentage of participants with CR,PR or hematologic improvement(HI) based on IWG Response Criteria. CR: BM:\<=5% myeloblasts with normal maturation of all cell lines; persistent dysplasia noted peripheral blood: hemoglobin (Hgb)\>=11 gram per deciliter (g/dL),platelets\>=100\*10\^9/L,neutrophils \>=1.0\*10\^9/L, blasts 0%. PR:CR criteria if abnormal before treatment except: BM blasts decreased by \>=50% from pretreatment but still\>5%; cellularity, morphology not relevant. HI criteria: Erythroid response:Hgb up by \>=1.5 g/dL; transfused RBC reduced by at least 4 red blood cell (RBC) transfusions/8 weeks comparatively last 8 weeks; Platelet response: Increase of \>=30\*10\^9/L for participants starting with \>20\*10\^9/L platelets; increase from \<20\*10\^9/L to \>20\*10\^9/L and by 100%; Neutrophil response: At least 100% and absolute increase \>0.5\*10\^9/L; Progression/relapse after HI: Granulocytes/platelets decreased by 50% from maximum; Hgb reduced by \>=1.5 g/dL; transfusion dependence.

Time frame:
From first dose up to 30 days after last dose of study drug or before start of subsequent antineoplastic therapy, whichever comes earlier up to Cycle 19 (up to Day 429, single agent)(Cycle=21 days) and Cycle 65 (up to Day 1850, combination)(Cycle=28 days)
Reported as:
Number · percentage of participants
ORR for Participants With MDS
percentage of participantsSingle Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2
ORR for Participants With MDS—01000
SecondaryPercentage of Participants With CR for Participants With AML

CR was defined as participant achieved the morphologic leukemia-free state and had an ANC of more than 1,000/mcL and platelets of \>=100,000/mcL. A morphologic leukemia-free state requires \<5% blasts in an aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. CR assessment was based on IWG Response Criteria.

Time frame:
From first dose up to 30 days after last dose of study drug or before start of subsequent antineoplastic therapy, whichever comes earlier up to Cycle 19 (up to Day 429, single agent)(Cycle=21 days) and Cycle 65 (up to Day 1850, combination)(Cycle=28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With CR for Participants With AML
percentage of participantsSingle Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2
Percentage of Participants With CR for Participants With AML00500
SecondaryPercentage of Participants With CR for Participants With MDS

CR was defined as participant with bone marrow: less than or equal to (\<=) 5% myeloblasts with normal maturation of all cell lines; persistent dysplasia was noted peripheral blood: Hgb \>=11 g/dL, platelets \>=100\*10\^9/L, neutrophils \>=1.0\*10\^9 per liter (/L), blasts 0%. CR assessment was based on IWG Response Criteria.

Time frame:
From first dose up to 30 days after last dose of study drug or before start of subsequent antineoplastic therapy, whichever comes earlier up to Cycle 19 (up to Day 429, single agent)(Cycle=21 days) and Cycle 65 (up to Day 1850, combination)(Cycle=28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With CR for Participants With MDS
percentage of participantsSingle Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2
Percentage of Participants With CR for Participants With MDS—000

Adverse events

Collected over TEAEs were adverse events that started after first dose through 30 days after the last dose of study drug: single agent arms (up to Cycle 19 [up to Day 429]) (Cycle=21 days); combination arms (up to Cycle 65 [up to Day 1850]) (Cycle=28 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Agent Arm: Pevonedistat 25 mg/m^21/3 (33.3%)2/3 (66.7%)3/3 (100%)
Single Agent Arm: Pevonedistat 44 mg/m^22/7 (28.6%)7/7 (100%)7/7 (100%)
Combination Arm: Pevonedistat 10 mg/m^2 + Azacitidine 75 mg/m^21/3 (33.3%)3/3 (100%)3/3 (100%)
Combination Arm: Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^21/10 (10%)6/10 (60%)10/10 (100%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventSingle Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2 + Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
PneumoniaInfections and infestations1/35/72/31/10
Febrile neutropeniaBlood and lymphatic system disorders0/33/70/30/10
Arthritis bacterialInfections and infestations0/30/71/30/10
Bronchopulmonary aspergillosisInfections and infestations1/30/70/30/10
CellulitisInfections and infestations0/30/71/30/10
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/71/30/10
Septic shockInfections and infestations0/30/71/30/10
Urinary tract infectionInfections and infestations0/30/71/30/10
Anal abscessInfections and infestations0/30/70/32/10
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/31/70/30/10
Most frequent other events
Showing 10 of 202
Most frequent other events
EventSingle Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2 + Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2
Back painMusculoskeletal and connective tissue disorders0/30/73/34/10
ConstipationGastrointestinal disorders1/33/72/37/10
Abdominal painGastrointestinal disorders0/30/72/32/10
Alanine aminotransferase increasedInvestigations1/30/72/33/10
AnaemiaBlood and lymphatic system disorders0/30/72/33/10
Aspartate aminotransferase increasedInvestigations1/31/72/33/10
Decreased appetiteMetabolism and nutrition disorders0/30/72/30/10
FatigueGeneral disorders1/32/72/31/10
Febrile neutropeniaBlood and lymphatic system disorders2/34/70/33/10
HypokalaemiaMetabolism and nutrition disorders0/32/72/33/10

Baseline characteristics

Safety population was defined as all enrolled participants who received at least 1 dose of any study drug, pevonedistat or azacitidine.

Age, Continuous
Age, Continuous(years)Single Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2Total
Mean78.0 ± 5.2069.0 ± 11.2765.0 ± 9.5464.9 ± 8.5267.9 ± 9.72
Sex: Female, Male
Sex: Female, Male(Participants)Single Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2Total
Female10034
Male273719
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Single Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2Total
Hispanic or Latino00000
Not Hispanic or Latino3731023
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2Total
American Indian or Alaska Native00000
Asian3731023
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Single Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2Total
Japan221712
Korea, South12014
Taiwan03227
Body Surface Area (BSA)
Body Surface Area (BSA)(square meter (m^2))Single Agent Arm: Pevonedistat 25 mg/m^2Single Agent Arm: Pevonedistat 44 mg/m^2Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2Total
Mean1.5 ± 0.261.7 ± 0.211.7 ± 0.041.7 ± 0.181.7 ± 0.20
08

Study locations

9 sites
  • Maebashi City, Japan
  • Nagoya, Japan
  • Sendai City, Japan
  • Tokyo, Japan
  • Chonnam National University Hwasun Hospital
    Jeonnam, 519-763, Korea, Republic of
  • Severance Hospital Yonsei University Health System - PPDS
    Seoul, 120-752, Korea, Republic of
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, 137701, Korea, Republic of
  • National Taiwan University Hospital
    Taipei, 10048, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 112, Taiwan
09

References and documents

Publications

  • Handa H, Cheong JW, Onishi Y, Iida H, Kobayashi Y, Kim HJ, Chiou TJ, Izutsu K, Tsukurov O, Zhou X, Faessel H, Yuan Y, Sedarati F, Faller DV, Kimura A, Wu SJ. Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine. J Hematol Oncol. 2022 May 11;15(1):56. doi: 10.1186/s13045-022-01264-w. PubMed 35545778 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Jan 2022, 68 months.

Results were first posted in Nov 2023, 1 year 9 months after primary completion.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 68 months is above that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2016
First posted
May 25, 2016
StartActual
May 16, 2016
Primary completionActual
Jan 25, 2022
CompletionActual
Jan 25, 2022
Results first posted
Nov 3, 2023
Last update
Nov 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02782468
Responsible party
Sponsor
First posted
May 25, 2016
Start date
May 16, 2016
Primary completion
Jan 25, 2022
Completion
Jan 25, 2022
Results posted
Nov 3, 2023
Last update
Nov 3, 2023

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pevonedistat · Azacitidine

Start the discussion